|
GBIO | Generation Bio Co. |
|
|
GBIO | Generation Bio Co. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.13 |
| Leverage | 58.52% |
| Market Cap | $ 375.6m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -62.5m |
| Margin | -357.68% |
Generation Bio Co., a genetic drug company, develops gene therapies for the treatment of rare and prevalent diseases. The company is headquartered in Cambridge, Massachusetts.